To clarify the clinical features and outcome of Stenotrophomonas maltophilia infection among hematopoietic SCT (HCT) recipients, we retrospectively reviewed the records of 1085 consecutive HCT recipients and identified 42 episodes in 31 HCT recipients with S. maltophilia infection. We compared these recipients with 30 non-HCT patients with S. maltophilia infection. The mortality rate in HCT recipients was significantly higher than that in non-HCT patients (relative risk 5.7, P ¼ 0.04), and we identified seven patients with pulmonary hemorrhage due to S. maltophilia, exclusively in the HCT cohort. Six of these latter seven patients died within 1 day from the onset of hemorrhage and the isolate was identified after death in most cases; one patient, who received empiric therapy for S. maltophilia and granulocyte transfusion, survived for more than 2 weeks. The patients with pulmonary hemorrhage had a more severe and longer duration of neutropenia, persistent fever despite of the use of broad-spectrum antibiotics, complication by pneumonia and higher C-reactive protein levels than those without pulmonary hemorrhage. In conclusion, S. maltophilia was associated with fulminant and fatal pulmonary hemorrhage in HCT recipients. Empiric therapy with antibiotics before the onset of pulmonary hemorrhage may be effective in HCT recipients who carry the conditions identified.
INTRODUCTION
Stenotrophomonas maltophilia is a non-fermentative, Gram-negative bacillus that is ubiquitous in the natural and hospital environment, [1] [2] [3] [4] and exhibits intrinsic resistance to many antibiotics including b-lactams, carbapenems and aminoglycosides. 5, 6 Although S. maltophilia is not usually highly virulent, it is a significant pathogen in immune-compromised patients, and the incidence of S. maltophilia infection is increasing. 7 Previously, in a heterogeneous group that included recipients of hematopoietic SCT (HCT) and non-HCT patients with solid tumor or hematological malignancy, risk factors for acquiring S. maltophilia infection were reported to be prolonged neutropenia, exposure to broad-spectrum antibiotics, mucositis, indwelling medical devices such as an intravascular catheter or ventilation tubes and long hospital stays. [8] [9] [10] [11] [12] In a similarly heterogeneous group, risk factors for mortality of S. maltophilia infection were reported to be neutropenia, hematological malignancy, immunosuppressive therapy, shock status at infection onset and intensive-care unit stays. [13] [14] [15] [16] [17] However, only limited information is available on HCT recipients. 12, 18, 19 Many of the previously reported risk factors are commonly seen in HCT recipients because of their severe immunosuppressive status and mucositis due to preparative conditioning and immunosuppressive therapy for GVHD prophylaxis.
Hence, S. maltophilia infection in HCT recipients may have a different spectrum and greater severity compared with that in patients with solid tumor or non-HCT setting hematological malignancy. To clarify the clinical features and outcome of S. maltophilia infection with a particular focus on HCT recipients, we retrospectively analyzed clinical data on patients who had S. maltophilia infection.
PATIENTS AND METHODS Patients
We retrospectively reviewed the medical and microbiological records of all the HCT recipients at the National Cancer Center Hospital (Tokyo, Japan) between January 2001 and December 2010, and identified episodes of S. maltophilia blood stream infection (BSI) among the HCT recipients. We also reviewed the medical and microbiological records of all patients whose blood cultures were positive for S. maltophilia at our institution in the same period and identified episodes of S. maltophilia BSI among the non-HCT patients. We then compared the clinical features and outcomes in the HCT cohort with those in the non-HCT control cohort.
Definitions
An episode of S. maltophilia BSI was defined as one or more positive blood cultures for S. maltophilia with clinical signs of infection. When S. maltophilia was again detected in the same patient at an interval of 8 or more days after the first BSI episode had improved, the detection of the isolate was regarded as a different episode of BSI, as previously reported. 13, 20 The severity of illness was assessed by the bacteremia score according to the University of Pittsburgh (PITT score). 21, 22 The D-index and cumulative D-index, which were calculated as the area over the neutrophil curve that is based on a graph plotting the absolute neutrophil counts during neutropenia, 23 were also investigated to evaluate the impact of both duration and severity of neutropenia on S. maltophilia infection.
Infection control in HCT recipients and microbiological investigations most cases, and in cases that did not improve within 2-3 days, either it was switched to carbapenem or vancomycin was added.
Two sets of blood culture samples from a double-lumen intravascular catheter and another from peripheral blood were routinely taken at the initial episode of fever. If fever persisted, one set of the blood culture samples was taken daily from either the lumen of the intravascular catheter or a peripheral vessel alternately. Blood culture samples were processed using a BACTEC 9240 (before 2008) or BACTEC FX (after 2009) system (Becton Dickinson Microbiology Systems, Sparks, MD, USA). Susceptibility to antibiotics was tested by the broth microdilution method according to the guidelines of the National Committee for Clinical Laboratory Standards.
Statistical analysis
The end point was defined as death within 4 weeks from the onset of a positive blood culture for S. maltophilia. Categorical variables were analyzed using a Chi-squared test or Fisher's exact test as appropriate. Continuous variables were compared using the Mann-Whitney U-test. To investigate risk factors for death within 4 weeks in all cases including both HCT and non-HCT cases, a multivariate logistic regression analysis was performed. The following factors were used as covariates: age (o45 vs X45 y), severe neutropenia at BSI onset, PITT score (p1 vs 41), complication by pneumonia and therapy for underlying disease (HCT vs non-HCT). The statistical analysis was performed with the SPSS 11.0 statistical software package (SPSS Inc, Tokyo, Japan).
RESULTS

Patient characteristics
In the study period between 2001 and 2010, a total of 1085 HCT (847 allogeneic HCT and 238 autologous HCT) procedures were performed in our institution. A total of 42 episodes (35 episodes in allogeneic HCT recipients and 7 episodes in autologous HCT recipients) of S. maltophilia BSI were identified in 31 HCT recipients (2.9%). There was no obvious outbreak of S. maltophilia infection in the study period.
The patient characteristics are shown in Table 1 . Broadspectrum cefem or carbapenem was administered in 60% of the episodes at BSI onset. With regard to the therapy for S. maltophilia infection, the intravascular catheter was removed in 10 (24%) episodes in which catheter-related BSI was suspected. When S. maltophilia BSI was diagnosed, ST or fluoroquinolone was started based on the susceptibility test in 19 episodes, whereas no antibiotics were additionally administered in 7 episodes where S. maltophilia was only detected in blood culture after death.
Clinical outcome
In all, 14 patients died within 4 weeks from the onset of a positive blood culture for S. maltophilia. We divided causes of death into two patterns; eight patients were judged to have died from a single cause due to S. maltophilia infection, whereas six appeared to have died of complex causes, which consisted of S. maltophilia infection and some other cause (underlying disease progression in two, GVHD in two, other infection in one and suffocation due to vomiting in one). Pulmonary hemorrhage accounted for half of the 14 deaths. Among the 847 allogeneic HCT recipients, 18 patients (2.1%) developed pulmonary hemorrhage (infection of S. maltophilia: n ¼ 7, Aspergillus species: n ¼ 3, Pseudomonas aeruginosa: n ¼ 1, Staphylococcus species: n ¼ 1, cytomegalovirus: n ¼ 1, idiopathic pneumonia syndrome/diffuse alveolar hemorrhage: n ¼ 2, disseminated intravascular coagulation: n ¼ 1, tumor invasion: n ¼ 1 and unknown cause: n ¼ 1).
Seven cases with pulmonary hemorrhage The details of the seven patients with pulmonary hemorrhage are shown in Table 2 . All the episodes of pulmonary hemorrhage occurred during a period of profound neutropenia (neutrophil count 0/mL).
As initial symptoms, all patients showed persistent fever that did not respond to broad-spectrum antibiotics. Other symptoms included chest pain (n ¼ 4), back pain (n ¼ 2), hemosputum (n ¼ 2) or dyspnea (n ¼ 1). Imaging test findings of chest X-ray (n ¼ 5) or computed tomography (n ¼ 5) in all patients showed consolidation that was consistent with symptoms such as chest pain. Six patients (cases 1-3 and 5-7) developed massive hemoptysis within 1-4 days after the initial chest symptoms. At the onset of massive hemoptysis, all the patients developed respiratory and circulatory failure due to bleeding and sepsis. Six patients, but not case 7, died within 1 day after hemoptysis. Because of the significantly rapid clinical course, S. maltophilia was detected in blood culture after death or 1 day before death in six patients (cases 1-6) and, similarly, S. maltophilia was detected in sputum culture after death in two patients (case 1 and 2).
Therapy for S. maltophilia was not initiated in three cases (cases 1-3) because the isolate was identified after death. In case 7, the administration of ST and pazufloxacin was started before the onset of hemoptysis and the identification of isolate because pulmonary hemorrhage due to S. maltophilia was suspected based on a typical clinical course and imaging test findings. Granulocyte transfusion was also started 38 h after the onset of hemoptysis and 28 h after the detection of S. maltophilia in blood culture. This patient survived for 16 and 15 days after the onset of hemoptysis and the identification of BSI, respectively. However, he eventually died due to S. maltophilia infection associated with primary graft failure. In case 5, the administration of ST and pazufloxacin was started before hemoptysis because he had a past history of S. maltophilia infection. The isolates exhibited resistance to the antibiotics used and he died within 1 day after hemoptysis. Bronchial arterial embolization was performed for pulmonary hemorrhage in two patients (case 1 and 5), however, neither were rescued.
Pulmonary hemorrhage due to S. maltophilia was diagnosed by the detection of S. maltophilia in blood and sputum cultures, histopathological findings of pulmonary hemorrhage and the presence of massive infiltration of Gram-negative rods in lungs by autopsy in three cases (cases 2, 3 and 5) (Figure 1 ). Cases 1 and 7 were diagnosed by the detection of S. maltophilia in blood and sputum cultures and the confirmation of pulmonary hemorrhage using bronchoscopy. Case 4 was diagnosed by the detection of S. maltophilia in blood and sputum cultures and clinical symptoms such as hemoptysis. Case 6 was diagnosed by the detection of S. maltophilia in blood culture and pulmonary hemorrhage confirmed by bronchoscopy.
Although the histopathological findings at autopsy in case 2 demonstrated one focal small nodule of aspergillosis in the right upper lobe, pulmonary hemorrhage was mainly found in the bilateral lower lobes, and therefore was mainly assumed to be due to S. maltophilia infection. There was no histopathological evidence of fungal infection in the other autopsy cases. Serum galactomannan Ag and b-D-glucan were tested at around the onset of pulmonary hemorrhage and results were negative in six cases, but not in case 2. The clinical characteristics and outcome in patients with and without pulmonary hemorrhage are compared in Table 3 . Patients with pulmonary hemorrhage were associated with severe and longer duration of neutropenia, higher C-reactive protein levels at BSI onset, a higher D-and cumulative D-index, a higher incidence of complication by pneumonia and higher mortality than those without pulmonary hemorrhage.
Comparison of HCT recipients with non-HCT patients
The clinical characteristics and outcomes of HCT recipients (42 episodes) were compared with those of 30 non-HCT patients (15 episodes with hematological malignancy and 15 with solid tumor) who developed S. maltophilia infection (Table 3) . HCT recipients were more likely to be associated with severe neutropenia (o100/mL), use of immunosuppressive agents and a higher mortality within 4 weeks after S. maltophilia BSI than non-HCT patients.
Although there was no significant difference in the proportion of patients with S. maltophilia pneumonia between the HCT recipients and non-HCT patients, pulmonary hemorrhage was seen only in HCT recipients. By a multivariate analysis in all the 72 episodes, including both HCT (n ¼ 42) and non-HCT cases (n ¼ 30), the independent risk factors for mortality within 4 weeks after S. maltophilia BSI were HCT recipient (relative risk 5.7, 95% confidence interval 1.1-30.1, P ¼ 0.04) and complication by pneumonia (relative risk 10.7, 95% confidence interval 2.6-44.2, P ¼ 0.001).
Susceptibility of strains of S. maltophilia from HCT recipients A total of 41 strains of S. maltophilia isolated from HCT recipients were tested with regard to their susceptibility to antibiotics. The percentages of isolates that were susceptible to ST (81%), minocycline (93%) and levofloxacin (68%) were relatively high, whereas fewer isolates were susceptible to ceftazidime (26%), amikacin (21%), cefepime (5%) and imipenem (3%). There were no significant differences in susceptibility to each antibiotic between isolates from HCT recipients and those from non-HCT patients. 
DISCUSSION
This is a retrospective study reporting the clinical characteristics and outcomes of S. maltophilia infection with a particular focus on HCT recipients. Our data revealed that HCT recipients who had S. maltophilia infection were more likely to be associated with pulmonary hemorrhage, which was the main cause of death in the cohort, and had a higher mortality within 4 weeks after S. maltophilia BSI than non-HCT patients. Previous studies of S. maltophilia infection in HCT recipients included many patients with catheter-related BSI and emphasized the removal of an intravascular catheter and the administration of appropriate antibiotics according to the results of a susceptibility test. 13, 18, 19 Our results were consistent with those of previous studies because 28 out of 42 episodes (67%) of S. maltophilia infection in this study were successfully treated. However, in previous reports that included S. maltophilia infection in HCT recipients, there was no information on pulmonary hemorrhage due to S. maltophilia. 13, 18, 19 Additionally, in previous large studies of post-transplant pulmonary hemorrhage, S. maltophilia had not been detected as a cause of pulmonary hemorrhage. [24] [25] [26] There have been only a few reported cases in a non-HCT setting that were associated with pulmonary hemorrhage due to S. maltophilia after intensive chemotherapy against hematological malignancy. [27] [28] [29] [30] Hence, this is the first report to comprehensively describe the overall picture of pulmonary hemorrhage due to S. maltophilia with a particular focus on HCT recipients, including the histopathological findings of autopsy, incidence, typical clinical course, risk factors and outcome.
By reviewing the medical records in detail, we identified the clinical characteristics of post-transplant pulmonary hemorrhage due to S. maltophilia. Risk factors for pulmonary hemorrhage due to S. maltophilia were HCT recipient, prolonged days of neutropenia, high C-reactive protein level at BSI onset and complication by pneumonia. In addition to the duration of neutropenia, the D-and cumulative D-index 23 were also considered to be factors that predicted pulmonary hemorrhage, whereas a high PITT score at the onset of BSI was not associated with pulmonary hemorrhage.
Typical findings that were recognized before pulmonary hemorrhage were persistent fever despite of the use of broadspectrum antibiotics, chest symptoms, such as chest pain, and apparent consolidation in imaging test. In many cases, it was impossible to start antibiotic therapy based on the identification of S. maltophilia infection in blood or sputum culture because most patients developed a very aggressive clinical course and died before the S. maltophilia infection was detected. Hence, S. maltophilia infection should be predicted in the HCT recipients based on the presence of risk factors for pulmonary hemorrhage due to S. maltophilia, and treatment for S. maltophilia infection should be considered before hemoptysis occurs.
In one of our cases (case 7 in Table 2 ), S. maltophilia infection was suspected based on typical findings and risk factors for pulmonary hemorrhage due to S. maltophilia, and empiric therapy that consisted of ST and pazufloxacin was started before hemoptysis and the detection of isolate. Granulocyte transfusion was also started, which resulted in a long survival after pulmonary hemorrhage was observed. This case suggests that empiric therapy for S. maltophilia infection might be useful if typical findings appear in HCT recipients who have risk factors for pulmonary hemorrhage due to S. maltophilia.
Current treatment recommendations for antibiotics against S. maltophilia are based on historical evidence, case series, case reports and in vitro susceptibility tests because of the lack of controlled trials. 1, 6 In general, ST has been shown to have the most potent and reliable in vitro activity against S. maltophilia, and alternate agents are new fluoroquinolone, tigecycline and ticarcillin-clavulanate. The isolates from both HCT recipients and non-HCT patients in our study were confirmed to have a high in vitro susceptibility to ST and new fluoroquinolone, however, tigecycline and ticarcillin-clavulanate were not tested because these drugs have not yet been approved in our country. Hence, ST alone or in combination with other susceptible agents is considered to be the treatment of choice for suspected or culture-proven S. maltophilia infection in HCT recipients. However, the myelotoxicity of ST might be a concern in the setting of HCT before engraftment.
The mechanism of S. maltophilia-induced pulmonary hemorrhage remains uncertain. In vitro data demonstrated that S. maltophilia produces proteases, which can break down the protein components of collagen, fibronectin and fibrinogen, 31, 32 and this may contribute to local tissue damage and hemorrhage. 1 Because our present histopathological findings at autopsy demonstrated alveolar hemorrhage and the massive infiltration of Gram-negative rods in lungs without invasion by neutrophils or lymphocytes, S. maltophilia itself might damage lung tissue, which leads to pulmonary hemorrhage. In an HCT recipient with a highly immunosuppressive background, it is speculated that S. maltophilia infects and proliferates in lung tissue, which is fragile due to chemotherapy or TBI as a preparative conditioning, and thus leads to pulmonary hemorrhage with a coexisting tendency for bleeding due to a low platelet count and coagulation disorder. Further molecular microbiological studies are warranted to clarify the mechanism of S. maltophilia-induced pulmonary hemorrhage.
Our results also showed that most patients who died without pulmonary hemorrhage had complex causes of death, such as underlying disease progression or uncontrolled GVHD in addition to S. maltophilia infection. This might be due to the fact that infections due to S. maltophilia occur often in patients in poor condition.
Our study has some limitations; it includes a relatively small number of patients in a single institution and uses a retrospective study design. However, this is the largest study to focus on S. maltophilia infection in HCT recipients and is the first study to report the significance of pulmonary hemorrhage as a cause of death.
In conclusion, we showed that S. maltophilia infection in HCT recipients is associated with higher mortality than that in non-HCT patients, and causes fulminant and fatal pulmonary hemorrhage, which is a main cause of death in HCT recipients with S. maltophilia infection. We also showed that patients with pulmonary hemorrhage were associated with persistent fever despite of the use of broad-spectrum antibiotics, complication by pneumonia, severe and significantly longer duration of neutropenia and higher C-reactive protein levels at the onset of BSI than those without pulmonary hemorrhage. Empiric therapy before the onset of pulmonary hemorrhage may be effective in HCT recipients who exhibit these identified conditions because most patients with pulmonary hemorrhage due to S. maltophilia die within a short period without the detection of infection. Multicenter prospective or retrospective studies that focus on HCT recipients are warranted to evaluate the optimum therapeutic strategy against this fatal and intrinsic multidrug-resistant microbe. Day from onset of neutropenia (o500/mL) or profound neutropenia (o100/mL) to recovery of neutropenia or profound neutropenia. If a patient died without recovery of neutropenia, days of neutropenia or profound neutropenia were counted until the day of mortality.
